You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

~ Buy the VIBATIV (telavancin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VIBATIV


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Vibativ

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00061633 ↗ Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed Cumberland Pharmaceuticals Phase 2 2003-06-01 Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.
NCT00061633 ↗ Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed Theravance Biopharma Antibiotics, Inc. Phase 2 2003-06-01 Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.
NCT00062647 ↗ Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Completed Cumberland Pharmaceuticals Phase 2 2003-08-01 The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
NCT00062647 ↗ Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Completed Theravance Biopharma Antibiotics, Inc. Phase 2 2003-08-01 The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
NCT00077675 ↗ Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed Cumberland Pharmaceuticals Phase 2 2004-02-01 Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
NCT00077675 ↗ Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed Theravance Biopharma Antibiotics, Inc. Phase 2 2004-02-01 Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vibativ

Condition Name

Condition Name for Vibativ
Intervention Trials
Staphylococcal Skin Infection 2
Gram-Positive Bacterial Infections 2
Infections, Gram-positive Bacterial 2
Bacterial Pneumonia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vibativ
Intervention Trials
Infections 5
Infection 5
Communicable Diseases 5
Staphylococcal Infections 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vibativ

Trials by Country

Trials by Country for Vibativ
Location Trials
United States 17
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vibativ
Location Trials
California 5
Louisiana 1
Massachusetts 1
Georgia 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vibativ

Clinical Trial Phase

Clinical Trial Phase for Vibativ
Clinical Trial Phase Trials
Phase 4 4
Phase 3 4
Phase 2 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vibativ
Clinical Trial Phase Trials
Completed 11
Recruiting 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vibativ

Sponsor Name

Sponsor Name for Vibativ
Sponsor Trials
Theravance Biopharma Antibiotics, Inc. 12
Cumberland Pharmaceuticals 10
Theravance Biopharma 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vibativ
Sponsor Trials
Industry 26
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.